Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial

H.S. van Meurs, P. Tajik, M.H. Hof, I. Vergote, G.G. Kenter, B.W. Mol, M.R. Buist, P.M. Bossuyt

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)3191-3201
JournalEuropean Journal of Cancer
Issue number15
Publication statusPublished - 2013

Cite this